PHARMACEUTICAL 2014

XOMA Royalty Corp
Rank 188 of 234



PHARMACEUTICAL 2014

XOMA Royalty Corp
Rank 188 of 234

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 6.1% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 112% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	127,060
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,645
Liabilities, Non-Current	35,150
Other Assets	1,266
Other Compr. Net Income	0
Other Expenses	4,945
Other Liabilities	73,974
Other Net Income	-61,236
Other Revenues	35,451
Property and Equipment	6,456
Research and Development	74,851
Selling, General and Administrative Expense	18,477

Output Variable	Value in 1000 USD
Assets	134,782
Liabilities	138,769
Expenses	98,273
Revenues	35,451
Stockholders Equity	-3,987
Net Income	-124,058
Comprehensive Net Income	-124,058
BaseVar	234,256
ECR before LimitedLiability	-97%
Economic Capital Ratio	131%